^
    Back
    Association details:
    Biomarker:EGFR positive
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:MRG003 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of MRG003 in Patients With Advanced Solid Tumors

    Excerpt:
    ...- Phase Ib: Patients with histologically and cytologically confirmed EGFR-positive advanced or metastatic colorectal cancer, squamous cell carcinoma of head and neck, and nasopharyngeal carcinoma...
    Trial ID:
    NCT04868344
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JAMA Oncol
    Title:

    Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial

    Published date:
    07/01/2022
    Excerpt:
    The findings of this nonrandomized clinical trial suggest that MRG003 showed a manageable safety profile and promising antitumor activity in patients with EGFR-positive NPC and SCCHN.
    DOI:
    10.1001/jamaoncol.2022.0503